These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 11814861)

  • 1. The new generation dihydropyridine type calcium blockers, bearing 4-phenyl oxypropanolamine, display alpha-/beta-adrenoceptor antagonist and long-acting antihypertensive activities.
    Liang JC; Yeh JL; Wang CS; Liou SF; Tsai CH; Chen IJ
    Bioorg Med Chem; 2002 Mar; 10(3):719-30. PubMed ID: 11814861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vanidipinedilol: a vanilloid-based beta-adrenoceptor blocker displaying calcium entry blocking and vasorelaxant activities.
    Yeh JL; Liou SF; Liang JC; Huang YC; Chiang LC; Wu JR; Lin YT; Chen IJ
    J Cardiovasc Pharmacol; 2000 Jan; 35(1):51-63. PubMed ID: 10630733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and antihypertensive activity of 1,4-dihydropyridine derivatives with a 4-(disubstituted phenyl) ring and an aminoalkyl ester group: highly potent and long-lasting calcium antagonists.
    Kanno H; Yamaguchi H; Okamiya Y; Sunakawa K; Takeshita T; Naruchi T
    Chem Pharm Bull (Tokyo); 1992 Aug; 40(8):2049-54. PubMed ID: 1423758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coumarin 1,4-dihydropyridine derivatives.
    Valenti P; Rampa A; Budriesi R; Bisi A; Chiarini A
    Bioorg Med Chem; 1998 Jun; 6(6):803-10. PubMed ID: 9681146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel 2-amino-1,4-dihydropyridine calcium antagonists. II. Synthesis and antihypertensive effects of 2-amino-1,4-dihydropyridine derivatives having N,N-dialkylaminoalkoxycarbonyl groups at 3- and/or 5-position.
    Kobayashi T; Inoue T; Nishino S; Fujihara Y; Oizumi K; Kimura T
    Chem Pharm Bull (Tokyo); 1995 May; 43(5):797-817. PubMed ID: 7553967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 1,4-Dihydropyridine derivatives as calcium channel modulators: the role of 3-methoxy-flavone moiety.
    Budriesi R; Bisi A; Ioan P; Rampa A; Gobbi S; Belluti F; Piazzi L; Valenti P; Chiarini A
    Bioorg Med Chem; 2005 May; 13(10):3423-30. PubMed ID: 15848754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-acting dihydropyridine calcium antagonists. 3. Synthesis and structure-activity relationships for a series of 2-[(heterocyclylmethoxy)methyl] derivatives.
    Alker D; Campbell SF; Cross PE; Burges RA; Carter AJ; Gardiner DG
    J Med Chem; 1989 Oct; 32(10):2381-8. PubMed ID: 2795609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel 1,4-dihydropyridine calcium antagonists. II. Synthesis and antihypertensive activity of 3-[4-(substituted amino)phenylalkyl]ester derivatives.
    Ashimori A; Ono T; Inoue Y; Morimoto S; Eda M; Uchida T; Ohtaki Y; Fujino Y; Kido H; Ogura Y
    Chem Pharm Bull (Tokyo); 1991 Jan; 39(1):91-9. PubMed ID: 2049813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Labedipinedilol-C: a third-generation dihydropyridine-type calcium channel antagonist displaying K+ channel opening, NO-dependent and adrenergic antagonist activities.
    Yeh JL; Liou SF; Liang JC; Lee CH; Chiu CC; Lin YT; Chen IJ
    J Cardiovasc Pharmacol; 2005 Aug; 46(2):130-40. PubMed ID: 16044023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel 2-amino-1,4-dihydropyridine calcium antagonists. I. Synthesis and antihypertensive effects of 2-amino-1,4-dihydropyridine derivatives having nitroxy-alkoxycarbonyl groups at 3- and/or 5-position.
    Kobayashi T; Inoue T; Kita Z; Yoshiya H; Nishino S; Oizumi K; Kimura T
    Chem Pharm Bull (Tokyo); 1995 May; 43(5):788-96. PubMed ID: 7553966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative QSAR studies of two series of 1,4-dihydropyridines as slow calcium channel blockers.
    Wikel JH; Bemis KG; Kurz K; Denney ML; Main BW; Moore RA; Smith T; Shingleton L; Holland DR
    Drug Des Discov; 1994 Jan; 11(1):1-14. PubMed ID: 8068815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and smooth muscle calcium channel effects of dialkyl 1,4-dihydro-2,6-dimethyl-4-aryl-3,5-pyridinedicarboxylates containing a nitrone moiety in the 4-aryl substituent.
    Anana RD; Ng H; Howlett SE; Knaus EE
    Arch Pharm (Weinheim); 1997 Mar; 330(3):53-8. PubMed ID: 9167447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-acting dihydropyridine calcium antagonists. 4. Synthesis and structure-activity relationships for a series of basic and nonbasic derivatives of 2-[(2-aminoethoxy)methyl]-1,4-dihydropyridine calcium antagonists.
    Alker D; Campbell SF; Cross PE; Burges RA; Carter AJ; Gardiner DG
    J Med Chem; 1990 Feb; 33(2):585-91. PubMed ID: 2153819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological properties of YM-15430-1, a 1,4-dihydropyridine derivative with beta 1-adrenoceptor-blocking activity.
    Shibasaki K; Uchida W; Shirai Y; Inagaki O; Asano M; Takenaka T
    Arch Int Pharmacodyn Ther; 1994; 328(2):213-24. PubMed ID: 7710306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and antihypertensive activities of new 1,4-dihydropyridine containing nitroimidazolyl substituent with a nitrooxy group at the 3-ester position.
    Shafiee A; Rastkary N; Jorjani M; Shafaghi B
    Arch Pharm (Weinheim); 2002 Mar; 335(2-3):69-76. PubMed ID: 12043457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-activity relationship studies of xanthone and fluorenone-1,4-dihydropyridine-5-phosphonates.
    Budriesi R; Rampa A; Bisi A; Fabbri G; Chiarini A; Valenti P
    Arzneimittelforschung; 1996 Apr; 46(4):374-7. PubMed ID: 8740081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis of 1,4-dihydropyridine-5-phosphonates and their calcium-antagonistic and antihypertensive activities: novel calcium-antagonist 2-[benzyl(phenyl)amino]ethyl 5-(5,5-dimethyl-2-oxo-1,3,2-dioxaphosphorinan-2-yl)-1,4-dihydro-2,6-dim ethyl-4-(3-nitrophenyl)-3-pyridinecarboxylate hydrochloride ethanol (NZ-105) and its crystal structure.
    Sakoda R; Kamikawaji Y; Seto K
    Chem Pharm Bull (Tokyo); 1992 Sep; 40(9):2362-9. PubMed ID: 1446356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and antihypertensive activities of new 1,4-dihydropyridine derivatives containing nitrooxyalkylester moieties at the 3- and 5-positions.
    Ogawa T; Nakazato A; Tsuchida K; Hatayama K
    Chem Pharm Bull (Tokyo); 1993 Jun; 41(6):1049-54. PubMed ID: 8370105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacologic characterization of FR172516: a new combined calcium channel-blocking and beta-adrenoceptor-blocking agent.
    Yamamoto N; Nomura M; Okubo K; Maeda K; Goto T
    J Cardiovasc Pharmacol; 1999 Apr; 33(4):587-94. PubMed ID: 10218729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis and pharmacological evaluation of new 1-[3-(4-arylpiperazin-1-yl)-2-hydroxy-propyl]-3,3-diphenylpyrrolidin-2-one derivatives with antiarrhythmic, antihypertensive, and alpha-adrenolytic activity.
    Kulig K; Sapa J; Nowaczyk A; Filipek B; Malawska B
    Eur J Med Chem; 2009 Oct; 44(10):3994-4003. PubMed ID: 19447527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.